Augmenting Radiation Sensitivity by Targeting PAR-Dependent Replication Fork Vulnerability in IDH- Mutant Glioma

Read the full article See related articles

Discuss this preprint

Start a discussion What are Sciety discussions?

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Mutations in isocitrate dehydrogenase 1 ( IDH1 ) drive the early stages of gliomagenesis while simultaneously imposing replication stress that creates targetable vulnerabilities. Using both in vitro and in vivo models, we show that inhibition of poly(ADP-ribose) glycohydrolase (PARG) induces a poly(ADP-ribose) (PAR)-dependent augmentation of radiosensitivity in IDH1 -mutant glioma cells. Metabolic repletion of NAD + fails to rescue this effect, indicating that the vulnerability cannot be explained solely by NAD + depletion. Instead, PARG inhibition profoundly alters replication fork progression and S-phase kinetics in IDH1 -mutant cells. Mechanistically, ionizing radiation preferentially activates replication fork-associated damage response proteins DNA-dependent protein kinase catalytic subunit (DNA-PKcs) and X-ray repair cross-complementing protein 1 (XRCC1) in IDH1 -mutant cells, a response partially reversed by pharmacologic inhibition of mutant IDH1 . Importantly, pharmacologic inhibition of DNA-PKcs with AZD7648 during irradiation disrupts fork-associated repair signaling and markedly enhances cytotoxicity in IDH1 -mutant glioma models. Together, these findings identify a PAR-dependent replication fork vulnerability that can be therapeutically exploited to selectively enhance radiosensitivity in IDH1 -mutant gliomas.

Statement of significance

IDH -mutant gliomas harbor intrinsic replication stress yet lack targeted radiosensitization strategies. We identify a PAR-dependent replication fork vulnerability in which disruption amplifies radiation cytotoxicity by deregulating S-phase fork signaling. Pharmacologic DNA-PKcs inhibition exploits this dependency, providing a genotype-selective approach to enhance radiotherapy in IDH -mutant glioma.

Article activity feed